Plain-English translation of NCT00901199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thalassemia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested whether using deferasirox and deferoxamine together was a safe and effective way to remove excess iron from the bodies of people with thalassemia who needed regular blood transfusions. The study followed patients for 12 months while they received both medications at doses tailored to how much iron their bodies had accumulated. Researchers measured changes in iron levels in the liver, heart, and blood to see how well the combination worked.
Patients with thalassemia who receive multiple blood transfusions accumulate dangerous levels of iron in their organs, which can damage the heart, liver, and other tissues. This trial investigated whether using this medication in combination with another iron-removing treatment might work better than either medication alone.
Participants received both medications for 12 months, with doses adjusted based on how much iron their bodies had at the start. During the trial, they had regular visits where doctors monitored iron levels in their liver and heart, checked their blood work, and watched for any side effects. This allowed researchers to carefully track whether the combination was working safely over the course of a year.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States